Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Jul 3;92(14):6439–6443. doi: 10.1073/pnas.92.14.6439

Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries.

P P Sanna 1, R A Williamson 1, A De Logu 1, F E Bloom 1, D R Burton 1
PMCID: PMC41533  PMID: 7604009

Abstract

Human monoclonal antibodies have considerable potential in the prophylaxis and treatment of viral disease. However, only a few such antibodies suitable for clinical use have been produced to date. We have previously shown that large panels of human recombinant monoclonal antibodies against a plethora of infectious agents, including herpes simplex virus types 1 and 2, can be established from phage display libraries. Here we demonstrate that facile cloning of recombinant Fab fragments against specific viral proteins in their native conformation can be accomplished by panning phage display libraries against viral glycoproteins "captured" from infected cell extracts by specific monoclonal antibodies immobilized on ELISA plates. We have tested this strategy by isolating six neutralizing recombinant antibodies specific for herpes simplex glycoprotein gD or gB, some of which are against conformationally sensitive epitopes. By using defined monoclonal antibodies for the antigen-capture step, this method can be used for the isolation of antibodies to specific regions and epitopes within the target viral protein. For instance, monoclonal antibodies to a nonneutralizing epitope can be used in the capture step to clone antibodies to neutralizing epitopes, or antibodies to a neutralizing epitope can be used to clone antibodies to a different neutralizing epitope. Furthermore, by using capturing antibodies to more immunodominant epitopes, one can direct the cloning to less immunogenic ones. This method should be of value in generating antibodies to be used both in the prophylaxis and treatment of viral infections and in the characterization of the mechanisms of antibody protective actions at the molecular level.

Full text

PDF
6439

Images in this article

6441Fig. 2
on p.6441
6441Fig. 3
on p.6441

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen W. P., Rapp F. Concept review of genital herpes vaccines. J Infect Dis. 1982 Mar;145(3):413–421. doi: 10.1093/infdis/145.3.413. [DOI] [PubMed] [Google Scholar]
  2. Burioni R., Williamson R. A., Sanna P. P., Bloom F. E., Burton D. R. Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):355–359. doi: 10.1073/pnas.91.1.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burke R. L. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. Rev Infect Dis. 1991 Nov-Dec;13 (Suppl 11):S906–S911. doi: 10.1093/clind/13.supplement_11.s906. [DOI] [PubMed] [Google Scholar]
  4. Burton D. R. Human monoclonal antibodies: achievement and potential. Hosp Pract (Off Ed) 1992 Aug 15;27(8):67–74. doi: 10.1080/21548331.1992.11705469. [DOI] [PubMed] [Google Scholar]
  5. Cai W. Z., Person S., Warner S. C., Zhou J. H., DeLuca N. A. Linker-insertion nonsense and restriction-site deletion mutations of the gB glycoprotein gene of herpes simplex virus type 1. J Virol. 1987 Mar;61(3):714–721. doi: 10.1128/jvi.61.3.714-721.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chanock R. M., Crowe J. E., Jr, Murphy B. R., Burton D. R. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases. Infect Agents Dis. 1993 Jun;2(3):118–131. [PubMed] [Google Scholar]
  7. Co M. S., Deschamps M., Whitley R. J., Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2869–2873. doi: 10.1073/pnas.88.7.2869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coen D. M. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res. 1991 May;15(4):287–300. doi: 10.1016/0166-3542(91)90010-o. [DOI] [PubMed] [Google Scholar]
  9. Dix R. D., Pereira L., Baringer J. R. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun. 1981 Oct;34(1):192–199. doi: 10.1128/iai.34.1.192-199.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eing B. R., Kühn J. E., Braun R. W. Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins. J Med Virol. 1989 Jan;27(1):59–65. doi: 10.1002/jmv.1890270113. [DOI] [PubMed] [Google Scholar]
  11. Eis-Hübinger A. M., Mohr K., Schneweis K. E. Different mechanisms of protection by monoclonal and polyclonal antibodies during the course of herpes simplex virus infection. Intervirology. 1991;32(6):351–360. doi: 10.1159/000150219. [DOI] [PubMed] [Google Scholar]
  12. Eis-Hübinger A. M., Schmidt D. S., Schneweis K. E. Anti-glycoprotein B monoclonal antibody protects T cell-depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes. J Gen Virol. 1993 Mar;74(Pt 3):379–385. doi: 10.1099/0022-1317-74-3-379. [DOI] [PubMed] [Google Scholar]
  13. Fujinaga S., Sugano T., Matsumoto Y., Masuho Y., Mori R. Antiviral activities of human monoclonal antibodies to herpes simplex virus. J Infect Dis. 1987 Jan;155(1):45–53. doi: 10.1093/infdis/155.1.45. [DOI] [PubMed] [Google Scholar]
  14. Fuller A. O., Lee W. C. Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration. J Virol. 1992 Aug;66(8):5002–5012. doi: 10.1128/jvi.66.8.5002-5012.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fuller A. O., Spear P. G. Specificities of monoclonal and polyclonal antibodies that inhibit adsorption of herpes simplex virus to cells and lack of inhibition by potent neutralizing antibodies. J Virol. 1985 Aug;55(2):475–482. doi: 10.1128/jvi.55.2.475-482.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gompels U., Minson A. The properties and sequence of glycoprotein H of herpes simplex virus type 1. Virology. 1986 Sep;153(2):230–247. doi: 10.1016/0042-6822(86)90026-7. [DOI] [PubMed] [Google Scholar]
  17. Hayashida I., Nagafuchi S., Hayashi Y., Kino Y., Mori R., Oda H., Ohtomo N., Tashiro A. Mechanism of antibody-mediated protection against herpes simplex virus infection in athymic nude mice: requirement of Fc portion of antibody. Microbiol Immunol. 1982;26(6):497–509. doi: 10.1111/j.1348-0421.1982.tb00203.x. [DOI] [PubMed] [Google Scholar]
  18. Highlander S. L., Sutherland S. L., Gage P. J., Johnson D. C., Levine M., Glorioso J. C. Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J Virol. 1987 Nov;61(11):3356–3364. doi: 10.1128/jvi.61.11.3356-3364.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hutchinson L., Goldsmith K., Snoddy D., Ghosh H., Graham F. L., Johnson D. C. Identification and characterization of a novel herpes simplex virus glycoprotein, gK, involved in cell fusion. J Virol. 1992 Sep;66(9):5603–5609. doi: 10.1128/jvi.66.9.5603-5609.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hwang C. B., Ruffner K. L., Coen D. M. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J Virol. 1992 Mar;66(3):1774–1776. doi: 10.1128/jvi.66.3.1774-1776.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kahlon J., Whitley R. J. Antibody response of the newborn after herpes simplex virus infection. J Infect Dis. 1988 Nov;158(5):925–933. doi: 10.1093/infdis/158.5.925. [DOI] [PubMed] [Google Scholar]
  22. Kohl S. The role of antibody in herpes simplex virus infection in humans. Curr Top Microbiol Immunol. 1992;179:75–88. doi: 10.1007/978-3-642-77247-4_5. [DOI] [PubMed] [Google Scholar]
  23. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  24. Ligas M. W., Johnson D. C. A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. J Virol. 1988 May;62(5):1486–1494. doi: 10.1128/jvi.62.5.1486-1494.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lipton H. L., Gonzalez-Scarano F. Central nervous system immunity in mice infected with theiler's virus. I. Local neutralizing antibody response. J Infect Dis. 1978 Feb;137(2):145–151. doi: 10.1093/infdis/137.2.145. [DOI] [PubMed] [Google Scholar]
  26. Mester J. C., Glorioso J. C., Rouse B. T. Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis. 1991 Feb;163(2):263–269. doi: 10.1093/infdis/163.2.263. [DOI] [PubMed] [Google Scholar]
  27. Navarro D., Paz P., Pereira L. Domains of herpes simplex virus I glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion. Virology. 1992 Jan;186(1):99–112. doi: 10.1016/0042-6822(92)90064-v. [DOI] [PubMed] [Google Scholar]
  28. Nugier F., Colin J. N., Aymard M., Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol. 1992 Jan;36(1):1–12. doi: 10.1002/jmv.1890360102. [DOI] [PubMed] [Google Scholar]
  29. Roop C., Hutchinson L., Johnson D. C. A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H. J Virol. 1993 Apr;67(4):2285–2297. doi: 10.1128/jvi.67.4.2285-2297.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Safrin S., Kemmerly S., Plotkin B., Smith T., Weissbach N., De Veranez D., Phan L. D., Cohn D. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis. 1994 Jan;169(1):193–196. doi: 10.1093/infdis/169.1.193. [DOI] [PubMed] [Google Scholar]
  31. Stanberry L. R., Harrison C. J., Bernstein D. I., Burke R. L., Shukla R., Ott G., Myers M. G. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy. Antiviral Res. 1989 May-Jun;11(4):203–214. doi: 10.1016/0166-3542(89)90005-3. [DOI] [PubMed] [Google Scholar]
  32. Straus S. E., Corey L., Burke R. L., Savarese B., Barnum G., Krause P. R., Kost R. G., Meier J. L., Sekulovich R., Adair S. F. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994 Jun 11;343(8911):1460–1463. doi: 10.1016/s0140-6736(94)92581-x. [DOI] [PubMed] [Google Scholar]
  33. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Williamson R. A., Burioni R., Sanna P. P., Partridge L. J., Barbas C. F., 3rd, Burton D. R. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci U S A. 1993 May 1;90(9):4141–4145. doi: 10.1073/pnas.90.9.4141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yoshida T., Suzutani T., Azuma M. Study on the apparent resistant strains of herpes simplex virus type 1 against 9-beta-D-arabinofuranosyladenine. Tohoku J Exp Med. 1988 Nov;156(3):279–290. doi: 10.1620/tjem.156.279. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES